These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25133381)

  • 1. ACP Journal Club. Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment.
    McCoy R; Smith S
    Ann Intern Med; 2014 Aug; 161(4):JC2. PubMed ID: 25133381
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus.
    Harel Z; Silver SA
    Evid Based Med; 2014 Dec; 19(6):218. PubMed ID: 25165155
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis].
    Divisón Garrote JA; Seguí Díaz M; Escobar Cervantes C
    Semergen; 2014 Oct; 40(7):399-400. PubMed ID: 25103068
    [No Abstract]   [Full Text] [Related]  

  • 6. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
    Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
    Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
    Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
    J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
    Yamaguchi K; Sata M
    Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACEIs for cardiovascular risk reduction--have we taken our eye off the ball?
    Sindone A; Erlich J; Perkovic V; Suranyi M; Newman H; Lee C; Barin E; Roger SD
    Aust Fam Physician; 2013 Sep; 42(9):634-8. PubMed ID: 24024224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mega clinical trials which have shaped the RAS intervention clinical practice.
    Düsing R
    Ther Adv Cardiovasc Dis; 2016 Jun; 10(3):133-50. PubMed ID: 27271312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Ravipati G; Aronow WS; Ahn C; Alappat RM; McClung JA; Weiss MB
    Am J Ther; 2009; 16(1):2-4. PubMed ID: 19114876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.